Company intelligence / Profile preview
PopVax
Hyderabad, Telangana, Indiapopvax.com ↗
- Ownership
- Private
- Employees
- ~70
- Development stage
- Preclinical
01
Overview
In preclinical studies, PopVax's COVID-19 vaccine constructs elicited an antibody response in mice that resulted in 10-100x more potent neutralization of key SARS-CoV-2 variants compared with sequences from existing mRNA COVID-19 vaccines approved in the U.S.[5]
- Therapeutic areas
- Infectious Diseases
- Modalities
- mRNA vaccineslipid nanoparticle (LNP) delivery
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
U.S. National Institute of Allergy and Infectious Diseases (NIAID)Bill & Melinda Gates FoundationBalvi
Beyond the preview
Go deeper on PopVax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PopVax.